Gynecomastia: Clinical evaluation and management

Indian Journal of Endocrinology and Metabolism

Volumn 18, Issue 2, 2014, Pages 150-158

  Cuhaci, Neslihan ^a   Polat, Sefika Burcak ^a   Evranos, Berna ^a   Ersoy, Reyhan ^a   Cakir, Bekir ^a  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

Androgen; drug; estrogen; gynecomastia; surgery

Indexed keywords

EID: 84995476535     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.129104     Document Type: Review

References (34)

1. Braunstein GD. Clinical Practise. Gynecomastia. N Engl J Med 2007;20:357:1229-37.
2. Carlson HE. Approach to the patient with gynecomastia. J Clin Endocrinol Metab 2011;96:15-21.
3. Johnson RE, Kermott CA, Murad MH. Gynecomastia-evaluation and current treatment options. Ther Clin Risk Manag 2011;7:145-8.
4. Daniels IR, Layer GT. Gynaecomastia. Eur J Surg 2001;167:885-92.
5. Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 2009;84:1010-5.
6. Rahmani S, Turton P, Shaaban A, Dall B. Owerview of gynecomastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. Breast J 2011;17:246-55.
7. Bhasin S. Testicular Disorders. In Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of Endocrinology. 11th ed. Philadelphia: Saunders Elsevier; 2008. p. 669-74.
8. Gikas P, Mokbel K. Management of gynaecomastia: an update. Int J Clin Pract 2007;61:1209-15.
9. Handschin AE, Bietry D, Hüsler R, Banic A, Constantinescu M. Surgical management of Gynecomastia-A 10 year analysis. World J Surg 2008;32:38-44.
10. Barros AC, Sampaio Mde C. Gynecomastia: Physiopathology, evaluation and treatment. Sao Paulo Med J 2012;130:187-97.
11. Bembo SA, Carlson HE. Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med 2004;71:511-7.
12. Ratnam BV. A new classification and treatment protocol for gynecomastia. Aesthet Surg J 2009;29:26-31.
13. Cordova A, Moschella F. Algorithm for clinical evaluation and surgical treatment of gynaecomastia. J Plast Reconstr Aesthet Surg 2008;61:41-9.
14. Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980;25:1-32.
15. Deepinder F, Braunstein GD. Drug-induced gynecomastia: An evidence-based review. Expert Opin Drug Saf 2012;11:779-95.
16. Magro G, Gangemi P, Villari L, Greco P. Deciduoid-like stromal cells in a diabetic patient with bilateral gynecomastia: A potential diagnostic pitfall. Virchows Arch 2004;445:659-60.
17. Kuhn JM, Roca R, Laudat MH, Rieu M, Luton JP, Bricaire H. Dies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol (Oxf) 1983;19:513-20.
18. Eberle AJ, Sparrow JT, Keenan BS. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr 1986;109:144-9.
19. Jones DJ, Holt SD, Surtees P, Davison DJ, Coptcoat MJ. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: Results of a prospective study in 55 patients. Ann R Coll Surg Engl 1990;72:296-8.
20. Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000;66:38-40.
21. Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: A double-blind crossover study. Metabolism 1986;35:705-8.
22. Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. Breast 2004;13:61-5.
23. Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in the management of gynaecomastia. Breast 2006;15:276-80.
24. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004;145:71-6.
25. Derman O, Kanbur NO, Kutluk T. Tamoxifen treatment for pubertal gynecomastia. Int J Adolesc Med Health 2003;15:359-63.
26. Alagaratnam TT. Idiopathic gynecomastia treated with tamoxifen: A preliminary report. Clin Ther 1987;9:483-7.
27. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428-33.
28. Binder G, Iliev DI, Dufke A, Wabitsch M, Schweizer R, Ranke MB, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: Hormonal, biochemical and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005;90:484-92.
29. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougnères P, Carel JC. Prepubertal gynecomastia in Peutz-Jeghers syndrome: Incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol 2006;154:221-7.
30. Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res 2004;16:95-7.
31. Dobs A, Darkes MJ. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 2005;174:1737-42.
32. Schröder FH, Collette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-Androgens: Is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000;82:283-90.
33. Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: A randomised, placebo-controlled, dose-response study. Eur Urol 2007;52:106-14.
34. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15.